These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31965889)

  • 1. Can CSF biomarkers predict future MS disease activity and severity?
    Magliozzi R; Cross AH
    Mult Scler; 2020 Apr; 26(5):582-590. PubMed ID: 31965889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light chain in the assessment of patients with multiple sclerosis.
    Domingues RB; Fernandes GBP; Leite FBVM; Senne C
    Arq Neuropsiquiatr; 2019 Jul; 77(6):436-441. PubMed ID: 31314847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cerebrospinal Fluid in Multiple Sclerosis.
    Deisenhammer F; Zetterberg H; Fitzner B; Zettl UK
    Front Immunol; 2019; 10():726. PubMed ID: 31031747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
    Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
    Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
    Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
    Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilaments as biomarkers in multiple sclerosis.
    Teunissen CE; Khalil M
    Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament and glial fibrillary acidic protein in multiple sclerosis.
    Norgren N; Sundström P; Svenningsson A; Rosengren L; Stigbrand T; Gunnarsson M
    Neurology; 2004 Nov; 63(9):1586-90. PubMed ID: 15534240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
    McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
    J Clin Lipidol; 2020; 14(5):675-684.e2. PubMed ID: 32758395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
    Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
    Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
    Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
    Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    van der Vuurst de Vries RM; Wong YYM; Mescheriakova JY; van Pelt ED; Runia TF; Jafari N; Siepman TA; Melief MJ; Wierenga-Wolf AF; van Luijn MM; Samijn JP; Neuteboom RF; Hintzen RQ
    Mult Scler; 2019 Jun; 25(7):958-967. PubMed ID: 29774770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
    Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
    J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
    Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament light chain level is a weak risk factor for the development of MS.
    Arrambide G; Espejo C; Eixarch H; Villar LM; Alvarez-Cermeño JC; Picón C; Kuhle J; Disanto G; Kappos L; Sastre-Garriga J; Pareto D; Simon E; Comabella M; Río J; Nos C; Tur C; Castilló J; Vidal-Jordana A; Galán I; Arévalo MJ; Auger C; Rovira A; Montalban X; Tintore M
    Neurology; 2016 Sep; 87(11):1076-84. PubMed ID: 27521440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.